S&P Cuts Idec to Hold

Also: analysts' opinions on Wellpoint and Advent Software

Idec Pharmaceutical (IDPH ): Downgrades to 3 STARS (hold) from 5 STARS (buy)

To continue reading this article you must be a Bloomberg Professional Service Subscriber.